New hope for brain tumors: drug targets genetic weakness
NCT ID NCT05588141
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called zotiraciclib in people with a certain type of brain tumor (glioma) that has come back after treatment. The tumor must have a specific gene mutation (IDH1 or IDH2). Participants take the drug by mouth in cycles. The goal is to see if the drug can slow tumor growth and to find the best dose with the fewest side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zotiraciclib
- What this could lead to
- If it works, this could offer a new treatment option to slow or stop the growth of recurrent IDH-mutant gliomas.
- What could go wrong
- This is an early-phase trial with a small number of participants. The drug may not be effective or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Can trained immune cells outsmart brain tumors?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare